Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
| Status: | Recruiting |
|---|---|
| Conditions: | Insomnia Sleep Studies, Lymphoma, Pulmonary, Pulmonary |
| Therapuetic Areas: | Oncology, Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/27/2019 |
| Start Date: | January 23, 2018 |
| End Date: | February 2023 |
| Contact: | Kevin Krull, PhD |
| Email: | referralinfo@stjude.org |
| Phone: | 866-278-5833 |
While thoracic radiation therapy (TRT) has been a primary component in successful treatment
of Hodgkin lymphoma, exposure to this treatment has been associated with significant
cardiovascular, cerebrovascular, and pulmonary morbidity in long-term survivors. Survivors of
Hodgkin lymphoma (HL) are also at risk for fatigue and excessive daytime sleepiness.
Insufficient sleep is recognized as an important public health concern, and is associated
with cardiovascular disease, diabetes, obesity, neurocognitive problems, and reduced quality
of life and productivity.
Survivors of HL, who are already at risk for cardiac and neurologic morbidity due to their
treatment exposures, could face catastrophic cardiovascular and cerebrovascular events with
the added risk associated with obstructive sleep apnea (OSA). The investigators propose to
examine indices of sleep quality using polysomnography, and associated neurocognitive
performance, brain MRI, and structure and strength of neck muscles in 220 long-term adult
survivors of Hodgkin lymphoma treated with thoracic radiation.
OBJECTIVES:
1. To estimate the prevalence of OSA in adult survivors of HL treated with thoracic
radiation, and compare the frequency to community controls matched on age, gender, race
and body mass index.
2. To identify specific therapeutic factors associated with OSA in adult survivors of HL
treated with thoracic radiation.
3. To identify biomarkers of OSA in adult survivors of HL treated with thoracic radiation.
4. To examine associations between OSA and cardiac morbidity and brain integrity in the
adult survivors of HL treated with thoracic radiation.
of Hodgkin lymphoma, exposure to this treatment has been associated with significant
cardiovascular, cerebrovascular, and pulmonary morbidity in long-term survivors. Survivors of
Hodgkin lymphoma (HL) are also at risk for fatigue and excessive daytime sleepiness.
Insufficient sleep is recognized as an important public health concern, and is associated
with cardiovascular disease, diabetes, obesity, neurocognitive problems, and reduced quality
of life and productivity.
Survivors of HL, who are already at risk for cardiac and neurologic morbidity due to their
treatment exposures, could face catastrophic cardiovascular and cerebrovascular events with
the added risk associated with obstructive sleep apnea (OSA). The investigators propose to
examine indices of sleep quality using polysomnography, and associated neurocognitive
performance, brain MRI, and structure and strength of neck muscles in 220 long-term adult
survivors of Hodgkin lymphoma treated with thoracic radiation.
OBJECTIVES:
1. To estimate the prevalence of OSA in adult survivors of HL treated with thoracic
radiation, and compare the frequency to community controls matched on age, gender, race
and body mass index.
2. To identify specific therapeutic factors associated with OSA in adult survivors of HL
treated with thoracic radiation.
3. To identify biomarkers of OSA in adult survivors of HL treated with thoracic radiation.
4. To examine associations between OSA and cardiac morbidity and brain integrity in the
adult survivors of HL treated with thoracic radiation.
Hodgkin lymphoma (HL) survivors being following at St. Jude within the SJLIFE protocol cohort
who were treated with TRT will be recruited to complete a comprehensive neurocognitive
evaluation, overnight polysomnography evaluation, brain and neck MRI, cervical strength
testing, and serum biomarkers related to cardiac disease. As part of their standard SJLIFE
evaluation, they will also complete an echocardiogram, pulmonary function tests and
questionnaires designed to evaluate broad health, emotional, socioeconomic and environmental
factors that impact everyday life.
The investigators will also recruit a comparison sample of healthy individuals matching on
age, sex, race and body mass index. The comparison group will complete the comprehensive
neurocognitive evaluation, overnight polysomnography, neck MRI, and cervical strength
testing.
who were treated with TRT will be recruited to complete a comprehensive neurocognitive
evaluation, overnight polysomnography evaluation, brain and neck MRI, cervical strength
testing, and serum biomarkers related to cardiac disease. As part of their standard SJLIFE
evaluation, they will also complete an echocardiogram, pulmonary function tests and
questionnaires designed to evaluate broad health, emotional, socioeconomic and environmental
factors that impact everyday life.
The investigators will also recruit a comparison sample of healthy individuals matching on
age, sex, race and body mass index. The comparison group will complete the comprehensive
neurocognitive evaluation, overnight polysomnography, neck MRI, and cervical strength
testing.
HODGKIN LYMPHOMA SURVIVOR ELIGIBILITY CRITERIA
Inclusion Criteria (Hodgkin Lymphoma Survivor):
- Current participant in the SJLIFE clinical trial ongoing at St. Jude Children's
Research Hospital (SJCRH) and was treated with thoracic radiation for Hodgkin lymphoma
- Currently ≥ 18 years of age
- ≥ 5 years from original diagnosis
Exclusion Criteria (Hodgkin Lymphoma Survivor):
- History of cranial or total-body radiation therapy
- History of intrathecal Methotrexate, high-dose Methotrexate, or high-dose Cytarabine.
- History of head injury or diagnosis of a genetic disorder associated with
neurocognitive impairment
- History of a neurodevelopmental disorder or birth complication associated with
neurocognitive impairment
- History of congenital heart disease reported in the literature to be associated with
neurocognitive status as determined by the PIs
- Currently pregnant
- Secondary central nervous system (CNS) neoplasm
COMPARISON GROUP (CONTROL) ELIGIBILITY CRITERIA
Inclusion Criteria (Comparison Group):
- Research participant is a sibling, parent, relative or friend of a current or former
St. Jude patient
- Research participant must be at least 18 years of age at the time of the scheduled
evaluation
Exclusion Criteria (Comparison Group):
- History of cranial, total-body or thoracic radiation therapy
- History of intrathecal Methotrexate, high-dose Methotrexate, or high-dose Cytarabine.
- History of head injury or diagnosis of a genetic disorder associated with
neurocognitive impairment
- History of a neurodevelopmental disorder or birth complication associated with
neurocognitive impairment
- History of congenital heart disease reported in the literature to be associated with
neurocognitive status as determined by the PIs
- Currently pregnant
- History of cancer
- 1st degree relative of a survivor included in the current study.
We found this trial at
1
site
262 Danny Thomas Pl
Memphis, Tennessee 38105
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Kevin Krull, PhD
Phone: 866-278-5833
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
Click here to add this to my saved trials
